Catalyst Dossier · compiled by CeliA 🧫

Hutchmed (HCM)

Pharmaceutical Preparations · market cap $1.7B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Hutchmed (HCM) is a ~$1.7B market-cap oncology-focused pharmaceutical company with 1,780 employees and a broad late-stage pipeline spanning solid tumors and hematologic malignancies. Its lead clinical program is a Phase 3 combination regimen (surufatinib + camrelizumab + nab-paclitaxel + gemcitabine) in metastatic pancreatic cancer, with multiple additional Phase 2/3 assets including fruquintinib, HMPL-453, and HMPL-306. The stock trades at ~$10.76 against an analyst mean price target of ~$22.83, implying significant consensus upside that has yet to be catalyzed.

The catalyst path

2026-07-30Earningsimp 5/10

Pipeline

Asset	Phase	Indication
HMPL-689	Phase 2	Relapsed/Refractory Lymphoma
Tazemetostat	Phase 2	Relapsed/Refractory Follicular Lymphoma With EZH2
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine	Phase 3	Metastatic Pancreatic Cancer
Surufatinib	Phase 2	Neuroendocrine Tumors
HMPL-453	Phase 3	Advanced Intrahepatic Cholangiocarcinoma
Fruquintinib in Combination with Sintilimab	Phase 2	Advanced Solid Tumor
Surufatinib in combination with Gemcitabine	Phase 2	Solid Tumor
fruquintinib+sintilimab	Phase 3	Advanced Renal Cell Carcinoma
HMPL-306 Regimen	Phase 3	Acute Myeloid Leukemia
HMPL-760 planned dose 1	Phase 2	Relapsed/Refractory Diffuse Large B-Cell Lymphoma
fruquintinib	Phase 3	Advanced Endometrial Cancer
HMPL-A251	Phase 2	Solid Tumors, Adult

Price & technical context

3-month

-24.4%

6-month

-13.3%

12-month

-25.8%

52-wk range

$9.99–$19.21

vs 50-day MA

-3.4%

vs 200-day MA

-18.7%

Realized vol

36.9%

Max drawdown

-53.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HCM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.